NL-OMON21751尚未招募不适用
Value-based healthcare for Inflammatory Bowel Disease: improving (cost-)effectiveness
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 3,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Treated in one of the eight hospitals
- •At least eighteen years of age
- •Have had a diagnosis of IBD for at least three months
- •Receive a biologic agent or tofacitinib as treatment for IBD. These are the biologics currently registered for the treatment of IBD (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab), and new treatments registered during the study period.
排除标准
- •Insufficient mastery of the Dutch language to fill in the questionnaires
- •No access to the internet to fill in the questionnaires
研究者
相似试验
已完成
不适用
Integrated care for inflammatory bowel disease patients in the Netherlands with the novel telemedicine tool myIBDcoach: a randomized controled trialCrohn's disease10017969ulcerative colitisNL-OMON41419niversiteit Maastricht909
尚未招募
1 期
To understand a patients dietary habits and causes of underweight during Inflammatory Bowel DiseaseCTRI/2018/07/015091MsPavithra devadiga
招募中
不适用
To study the profile of inflammatory bowel disease (both ulcerative colitis and crohns disease) in IndiaCTRI/2020/08/027486Dayanand Medical College and Hospital Ludhiana
招募中
不适用
Inflammatory Bowel Disease TrackerInflammatory bowel disease - Crohn's disease or ulcerative colitis10017969NL-OMON46657Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology50
已完成
不适用
Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled TrialInflammatory Bowel DiseaseNCT02173002Maastricht University Medical Center909